The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synuclein Seed Amplification Assay Program, 2024Maximizing Sensitivity of Alpha-synuclein Seed Amplification Assays by Eliminating Spontaneous Aggregation
Study Rationale: A key characteristic of Parkinson’s disease (PD) is the formation of alpha-synuclein aggregates in the brain. The ability to detect these aggregates in body fluids is important for...
-
Freezing of Gait, 2024Use of Soft Robotic Apparel to Prevent Freezing of Gait in Parkinson’s Disease
Study Rationale: Freezing of gait (FoG) is a disabling walking problem that leads to loss of mobility, falling and poor quality of life in many people with Parkinson’s disease (PD). People with FoG...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Interrogating Novel Defects in Protein Glycosylation in GBA1-associated Parkinson’s Disease
Study Rationale: Sugars are added to proteins in a process called glycosylation. The precise manner in which these sugars are added is critical for the proper function of the resulting glycoproteins...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of an Angiotensin-(1-7) Glycopeptide, to Treat Dementia in Parkinson's Disease
Study Rationale: Peptide-based drugs are attractive candidates for treating the cognitive decline associated with Parkinson’s disease (PD) because they demonstrate a robust safety profile and an...
-
Research Grant, 2024(SUPPLEMENT) Investigation of Small Molecules for Rescuing Lysosomal and GBA1 Deficiencies in GBA-associated Parkinson’s Disease
Study Rationale: Individuals with mutations in the GBA1 gene encoding the enzyme β-glucocerebrosidase (GCase) have a higher risk of Parkinson’s disease (PD). Gaucher disease, a rare genetic disease...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Clinical Trial to Investigate the Safety of Repeated Subcutaneous Injections of HER-096, a Novel Candidate for Disease-modifying Therapy in Parkinson’s Disease
Study Rationale: sHER-096 is a novel compound that mimics CDNF, a human neurotrophic factor that has shown neuroprotective and neurorestorative properties in an animal model of Parkinson’s disease (PD...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.